(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600420 · · 11 pages · Chinese
Shanghai Shyndec Pharmaceutical Co., Ltd. on 6ix
Earlier from Shanghai Shyndec Pharmaceutical
- (600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Progress of Signing of the Drug Marketing Authorization Transfer Contract by Controlled Subsidiary
- (600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate
- (600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Performance Forecast for the First Three Quarters of 2026
- Announcement on Progress of Provision of Guarantees by a Wholly-owned Subsidiary to Its Subordinate Enterprise
- Announcement on Implementation of Dividend Distribution for the First Half of 2026
Later from Shanghai Shyndec Pharmaceutical
- (600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction
- (600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate by Wholly-owned Subsidiary
- (600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Withdrawal of Drug Registration Application by Controlled Subsidiary
- (600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Controlled Subsidiary Passing the Drug GMP Compliance Inspection
Follow Shanghai Shyndec Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Shyndec Pharmaceutical